Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromium-51 labelled cultured red cells is an investigational radiolabelled cellular product developed by Cell Therapies Pty Ltd. It consists of cultured red blood cells (cRBCs) that are labelled ex vivo with the radioactive isotope chromium-51 (51Cr) using a sterile sodium chromate solution. The product is designed for intravenous administration to evaluate the mean circulation time, biodistribution, and safety of cultured red cells in patients with low-risk myelodysplastic syndrome (MDS) or those in remission from hematologic malignancies. The chromium-51 label serves as a diagnostic tracer for in vivo tracking via gamma scintigraphy, allowing researchers to monitor the survival and movement of the infused cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chromium-51 labelled cultured red cells.